Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ): Innovative Drug BIOS-0623-Z4 Tablets Receives Clinical Trial Approval

Stock News09-29

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that the company has recently received notification that its independently developed innovative drug BIOS-0623-Z4 tablets has obtained clinical trial approval from the National Medical Products Administration (NMPA). BIOS-0623-Z4 tablets is an independently developed non-opioid targeted mechanism drug for adult cancer pain treatment. Currently, no drug with the same target and indication is available on the market. BIOS-0623-Z4 tablets is classified as an "innovative drug not marketed domestically or internationally," with a registration classification of chemical drug category 1.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165755739?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165755739","market":"sg","top_or_hot":-1,"title":"Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ): Innovative Drug BIOS-0623-Z4 Tablets Receives Clinical Trial Approval","media":"Stock News","content":"<p>Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that the company has recently received notification that its independently developed innovative drug BIOS-0623-Z4 tablets has obtained clinical trial approval from the National Medical Products Administration (NMPA). BIOS-0623-Z4 tablets is an independently developed non-opioid targeted mechanism drug for adult cancer pain treatment. Currently, no drug with the same target and indication is available on the market. BIOS-0623-Z4 tablets is classified as an \"innovative drug not marketed domestically or internationally,\" with a registration classification of chemical drug category 1.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ): Innovative Drug BIOS-0623-Z4 Tablets Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ): Innovative Drug BIOS-0623-Z4 Tablets Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-29 17:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that the company has recently received notification that its independently developed innovative drug BIOS-0623-Z4 tablets has obtained clinical trial approval from the National Medical Products Administration (NMPA). BIOS-0623-Z4 tablets is an independently developed non-opioid targeted mechanism drug for adult cancer pain treatment. Currently, no drug with the same target and indication is available on the market. BIOS-0623-Z4 tablets is classified as an \"innovative drug not marketed domestically or internationally,\" with a registration classification of chemical drug category 1.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06978","symbol_name":"永泰生物-B","start_time":0,"source_url":"","article_id":"1165755739","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165755739","pubTimestamp":1759137091,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that the company has recently received notification that its independently developed innovative drug BIOS-0623-Z4 tablets has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","301096":"百诚医药","06978":"永泰生物-B","BK1574":"生物医药B类股","BK0216":"研究试验","BK1161":"生物科技"},"translate_title":"杭州生物诚信医药科技有限公司。（301096.SZ）：创新药BIOS-0623-Z4片获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"301096":1,"06978":1},"content_text":"Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that the company has recently received notification that its independently developed innovative drug BIOS-0623-Z4 tablets has obtained clinical trial approval from the National Medical Products Administration (NMPA). BIOS-0623-Z4 tablets is an independently developed non-opioid targeted mechanism drug for adult cancer pain treatment. Currently, no drug with the same target and indication is available on the market. BIOS-0623-Z4 tablets is classified as an \"innovative drug not marketed domestically or internationally,\" with a registration classification of chemical drug category 1.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165755739","isCrawlerRequest":true}